Mechanisms and Treatment of Intradialytic Hypertension - Sodium (NCT01371890) | Clinical Trial Compass
CompletedNot Applicable
Mechanisms and Treatment of Intradialytic Hypertension - Sodium
United States18 participantsStarted 2011-05
Plain-language summary
The purpose of this study is to determine the role of dialysate exposure and fluid removal during hemodialysis in the pathophysiology of intradialytic hypertension.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* on hemodialysis \> 30 days
* male and female participants, aged 18 to 85 years old, of all races and ethnic origin
* ability to provide informed consent
* Primary nephrologist deems patient is at target dry weight
* KDOQI defined hypertension (predialysis SBP \>140 or postdialysis SBP\>130) AND
* pre to post hemodialysis SBP increase (\>10 mmHg) during 4/6 last HD session
Exclusion Criteria:
* Patients with active cancer or active wounds
* Patient currently on antibiotics or on IV antibiotics within the last month
* BP unable to be measured by routine mechanisms in the upper extremity
* Life expectancy \< 6 months
* Inability to provide informed consent
* Larger interdialytic weight gain (\>5 kg/treatment on average)
What they're measuring
1
Systolic blood pressure
Timeframe: crossover studies followup 3-16 weeks
Trial details
NCT IDNCT01371890
SponsorUniversity of Texas Southwestern Medical Center